RUBICONRubicon Research Limited
Pharma · Drug Manufacturers - General · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
Rubicon Research Limited operates as a specialty pharmaceutical company in India, the United States, and internationally. Its primary proprietary technologies for drug delivery comprising RubiSRL for the formulation of sustained release liquids using a combination of ion exchange and membrane diffusion controlled-release technologies; and RubiReten, a gastro-retentive system for drugs with poor solubility and a limited window of absorption. The company develops products in the areas of analgesics/pain management, hypokalemia, gastrointestinal, cardiovascular, skeletal muscle relaxants, metabolic, central nervous system, nicotine replacement therapy, and immunosuppressant. The company was incorporated in 1999 and is based in Mumbai, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
The picture
- • Revenue growth: 51.6% YoY
- • Profit growth: 82.1% YoY
- • ROE: 19.1%
- • Price vs SMA200: above
- • Golden cross setup: SMA50 above SMA200
- • Trend strength (ADX): 37
- • RSI Oversold Reversal signal (setup quality 55%)
Bull case
- • Revenue growth: 51.6% YoY
- • Profit growth: 82.1% YoY
- • ROE: 19.1%
- • Price vs SMA200: above
Bear case
- • Valuation vs sector: P/E 85.8 vs sector 35.5
- • Dividend yield: 0.08%
- • RSI: 39
- • MACD: bearish
Key risks
- • Momentum is fading versus the broader market
- • Valuation vs sector: P/E 85.8 vs sector 35.5
- • Dividend yield: 0.08%
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹62.20). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.